139 related articles for article (PubMed ID: 29994908)
21. Dose-volume histogram predictors of chronic gastrointestinal complications after radical hysterectomy and postoperative intensity modulated radiotherapy for early-stage cervical cancer.
Chen Z; Zhu L; Zhang B; Meng M; Yuan Z; Wang P
BMC Cancer; 2014 Oct; 14():789. PubMed ID: 25354964
[TBL] [Abstract][Full Text] [Related]
22. Intensity-modulated radiotherapy reduces gastrointestinal toxicity in pelvic radiation therapy with moderate dose.
Kwak YK; Lee SW; Kay CS; Park HH
PLoS One; 2017; 12(8):e0183339. PubMed ID: 28846718
[TBL] [Abstract][Full Text] [Related]
23. Intensity-modulated radiation therapy versus three-dimensional conformal radiation therapy with concurrent nedaplatin-based chemotherapy after radical hysterectomy for uterine cervical cancer: comparison of outcomes, complications, and dose-volume histogram parameters.
Isohashi F; Mabuchi S; Yoshioka Y; Seo Y; Suzuki O; Tamari K; Yamashita M; Unno H; Kinose Y; Kozasa K; Sumida I; Otani Y; Kimura T; Ogawa K
Radiat Oncol; 2015 Aug; 10():180. PubMed ID: 26300325
[TBL] [Abstract][Full Text] [Related]
24. Clinical outcomes of definitive intensity-modulated radiation therapy with fluorodeoxyglucose-positron emission tomography simulation in patients with locally advanced cervical cancer.
Kidd EA; Siegel BA; Dehdashti F; Rader JS; Mutic S; Mutch DG; Powell MA; Grigsby PW
Int J Radiat Oncol Biol Phys; 2010 Jul; 77(4):1085-91. PubMed ID: 19880262
[TBL] [Abstract][Full Text] [Related]
25. Normal tissue complication probability analysis of acute gastrointestinal toxicity in cervical cancer patients undergoing intensity modulated radiation therapy and concurrent cisplatin.
Simpson DR; Song WY; Moiseenko V; Rose BS; Yashar CM; Mundt AJ; Mell LK
Int J Radiat Oncol Biol Phys; 2012 May; 83(1):e81-6. PubMed ID: 22516388
[TBL] [Abstract][Full Text] [Related]
26. The prognostic factors for locally advanced cervical cancer patients treated by intensity-modulated radiation therapy with concurrent chemotherapy.
Chen CC; Wang L; Lin JC; Jan JS
J Formos Med Assoc; 2015 Mar; 114(3):231-7. PubMed ID: 25777974
[TBL] [Abstract][Full Text] [Related]
27. Comparison of genitourinary and gastrointestinal toxicity among four radiotherapy modalities for prostate cancer: Conventional radiotherapy, intensity-modulated radiotherapy, and permanent iodine-125 implantation with or without external beam radiotherapy.
Sutani S; Ohashi T; Sakayori M; Kaneda T; Yamashita S; Momma T; Hanada T; Shiraishi Y; Fukada J; Oya M; Shigematsu N
Radiother Oncol; 2015 Nov; 117(2):270-6. PubMed ID: 26318662
[TBL] [Abstract][Full Text] [Related]
28. Clinical toxicities and dosimetric parameters after whole-pelvis versus prostate-only intensity-modulated radiation therapy for prostate cancer.
Deville C; Both S; Hwang WT; Tochner Z; Vapiwala N
Int J Radiat Oncol Biol Phys; 2010 Nov; 78(3):763-72. PubMed ID: 20171807
[TBL] [Abstract][Full Text] [Related]
29. Comparison of acute and subacute genitourinary and gastrointestinal adverse events of radiotherapy for prostate cancer using intensity-modulated radiation therapy, three-dimensional conformal radiation therapy, permanent implant brachytherapy and high-dose-rate brachytherapy.
Morimoto M; Yoshioka Y; Konishi K; Isohashi F; Takahashi Y; Ogata T; Koizumi M; Teshima T; Bijl HP; van der Schaaf A; Langendijk JA; Ogawa K
Tumori; 2014; 100(3):265-71. PubMed ID: 25076236
[TBL] [Abstract][Full Text] [Related]
30. Adjuvant concurrent chemoradiotherapy with intensity-modulated pelvic radiotherapy after surgery for high-risk, early stage cervical cancer patients.
Chen MF; Tseng CJ; Tseng CC; Yu CY; Wu CT; Chen WC
Cancer J; 2008; 14(3):200-6. PubMed ID: 18536561
[TBL] [Abstract][Full Text] [Related]
31. Predictors of grade 3 or higher late bowel toxicity in patients undergoing pelvic radiation for cervical cancer: results from a prospective study.
Chopra S; Dora T; Chinnachamy AN; Thomas B; Kannan S; Engineer R; Mahantshetty U; Phurailatpam R; Paul SN; Shrivastava SK
Int J Radiat Oncol Biol Phys; 2014 Mar; 88(3):630-5. PubMed ID: 24521678
[TBL] [Abstract][Full Text] [Related]
32. Comparison of dosimetric parameters and acute toxicity of intensity-modulated and three-dimensional radiotherapy in patients with cervix carcinoma: A randomized prospective study.
Naik A; Gurjar OP; Gupta KL; Singh K; Nag P; Bhandari V
Cancer Radiother; 2016 Jul; 20(5):370-6. PubMed ID: 27368915
[TBL] [Abstract][Full Text] [Related]
33. Treatment-Related Radiation Toxicity Among Cervical Cancer Patients.
Rubinsak LA; Kang L; Fields EC; Carter JS; McGuire WP; Temkin SM
Int J Gynecol Cancer; 2018 Sep; 28(7):1387-1393. PubMed ID: 30036222
[TBL] [Abstract][Full Text] [Related]
34. Image-guided, intensity-modulated radiation therapy in definitive radiotherapy for 1433 patients with cervical cancer.
Wang W; Zhang F; Hu K; Hou X
Gynecol Oncol; 2018 Dec; 151(3):444-448. PubMed ID: 30266261
[TBL] [Abstract][Full Text] [Related]
35. Intensity-modulated radiation therapy for advanced cervical cancer: a comparison of dosimetric and clinical outcomes with conventional radiotherapy.
Du XL; Tao J; Sheng XG; Lu CH; Yu H; Wang C; Song QQ; Li QS; Pan CX
Gynecol Oncol; 2012 Apr; 125(1):151-7. PubMed ID: 22198339
[TBL] [Abstract][Full Text] [Related]
36. High-dose intensity-modulated radiation therapy as primary treatment of prostate cancer: genitourinary/gastrointestinal toxicity and outcomes, a single-institution experience.
Detti B; Baki M; Becherini C; Saieva C; Scartoni D; Giacomelli I; Trombetta L; Muntoni C; Olmetto E; Francolini G; Turkaj A; Topulli J; Ciabatti C; Carta G; Poggesi L; Delli Paoli C; Terziani F; Grassi R; Livi L
Radiol Med; 2019 May; 124(5):422-431. PubMed ID: 30607866
[TBL] [Abstract][Full Text] [Related]
37. Improved toxicity profile following high-dose postprostatectomy salvage radiation therapy with intensity-modulated radiation therapy.
Goenka A; Magsanoc JM; Pei X; Schechter M; Kollmeier M; Cox B; Scardino PT; Eastham JA; Zelefsky MJ
Eur Urol; 2011 Dec; 60(6):1142-8. PubMed ID: 21855208
[TBL] [Abstract][Full Text] [Related]
38. Role of Surgical Versus Clinical Staging in Chemoradiated FIGO Stage IIB-IVA Cervical Cancer Patients-Acute Toxicity and Treatment Quality of the Uterus-11 Multicenter Phase III Intergroup Trial of the German Radiation Oncology Group and the Gynecologic Cancer Group.
Marnitz S; Martus P; Köhler C; Stromberger C; Asse E; Mallmann P; Schmidberger H; Affonso Júnior RJ; Nunes JS; Sehouli J; Budach V
Int J Radiat Oncol Biol Phys; 2016 Feb; 94(2):243-53. PubMed ID: 26853333
[TBL] [Abstract][Full Text] [Related]
39. Prophylactic lower para-aortic irradiation using intensity-modulated radiotherapy mitigates the risk of para-aortic recurrence in locally advanced cervical cancer: A 10-year institutional experience.
Lee J; Lin JB; Chang CL; Jan YT; Sun FJ; Wu MH; Chen YJ
Gynecol Oncol; 2017 Jul; 146(1):20-26. PubMed ID: 28457584
[TBL] [Abstract][Full Text] [Related]
40. Low-dose, prophylactic, extended-field, intensity-modulated radiotherapy plus concurrent weekly cisplatin for patients with stage IB2-IIIB cervical cancer, positive pelvic lymph nodes, and negative para-aortic lymph nodes.
Liang JA; Chen SW; Hung YC; Yeh LS; Chang WC; Lin WC; Chang YY
Int J Gynecol Cancer; 2014 Jun; 24(5):901-7. PubMed ID: 23975081
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
